Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    22901886 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Condition: Asthma
Interventions: Biological: Mepolizumab 750;   Biological: Mepolizumab 250;   Biological: Mepolizumab 75;   Drug: Placebo saline
2 Enrolling by invitation Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
Conditions: Severe Persistent Asthma;   Eosinophilic Bronchitis
Interventions: Biological: Reslizumab;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.